In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents

Journal of Global Antimicrobial Resistance

Volumn 10, Issue , 2017, Pages 326-329

  Jacqueline, Cédric ^a   Howland, Karen ^b   Chesnel, Laurent ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antibacterial; Ceftolozane tazobactam; Chequerboard analysis; Combination therapy; Gram negative pathogens; Outcome

Indexed keywords

AMIKACIN; AZTREONAM; CEFTOLOZANE PLUS TAZOBACTAM; MEROPENEM; METRONIDAZOLE; TIGECYCLINE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; COMBINATION DRUG THERAPY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

AMIKACIN; AZTREONAM; CEPHALOSPORINS; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; HUMANS; MEROPENEM; MICROBIAL SENSITIVITY TESTS; TAZOBACTAM; TIGECYCLINE;

EID: 85026290787     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2017.04.003     Document Type: Article

References (17)

1. Tamma, P.D., Cosgrove, S.E., Maragakis, L.L., Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25 (2012), 450–470.
2. Fischbach, M.A., Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14 (2011), 519–523.
3. Sader, H.S., Rhomberg, P.R., Farrell, D.J., Jones, R.N., Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55 (2011), 2390–2394.
4. Zhanel, G.G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 74 (2014), 31–51.
5. Merck Sharp & Dohme, Corp, Zerbaxa (ceftolozane and tazobactam) prescribing information. 2015, Merck Sharp & Dohme, Corp., Whitehouse Station, NJ.
6. Pfaller, M.A., Bassetti, M., Duncan, L.R., Castanheira, M., Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother 72 (2017), 1386–1395.
7. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. tenth edition, 2015, CLSI, Wayne, PA Document M07-A10.
8. Garrod, L.P., Waterworth, P.M., Methods of testing combined antibiotic bactericidal action and the significance of the results. J Clin Pathol 15 (1962), 328–338.
9. Lorian, V., Antibiotics in laboratory medicine. 2005, Lippincott Williams & Wilkins, Philadelphia, PA.
10. Smith, J.R., Arya, A., Yim, J., Barber, K.E., Hallesy, J., Singh, N.B., et al. Daptomycin in combination with ceftolozane–tazobactam or cefazolin against daptomycin-susceptible and -nonsusceptible Staphylococcus aureus in an in vitro, hollow-fiber model. Antimicrob Agents Chemother 60 (2016), 3970–3975.
11. Quale, J., Bratu, S., Gupta, J., Landman, D., Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50 (2006), 1633–1641.
12. Rodriguez-Martinez, J.M., Poirel, L., Nordmann, P., Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53 (2009), 4783–4788.
13. Dean, C.R., Visalli, M.A., Projan, S.J., Sum, P.E., Bradford, P.A., Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47 (2003), 972–978.
14. Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., Hatano, K., In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51 (2007), 826–830.
15. Vidaillac, C., Leonard, S.N., Sader, H.S., Jones, R.N., Rybak, M.J., In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 53 (2009), 2360–2366.
16. Dallow, J., Otterson, L.G., Huband, M.D., Krause, K.M., Nichols, W.W., Microbiological interaction studies between ceftazidime–avibactam and pulmonary surfactant and between ceftazidime–avibactam and antibacterial agents of other classes. Int J Antimicrob Agents 44 (2014), 552–556.
17. Dassner, A.M., Sutherland, C., Girotto, J., Nicolau, D.P., In vitro activity of ceftolozane/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients. Infect Dis Ther 6 (2017), 129–136.